From the Journals

Dermatologic complaints prolong hospital stay for hematologic cancer


 

FROM THE JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

In-hospital dermatologic consults are more than six times more likely to occur in patients with hematologic malignancies than in those with solid tumors and are associated with an increased mean length of hospital stay, according to a large retrospective chart review from a major cancer center.

The substantial burden imposed by dermatologic complications in patients with cancer, particularly a hematologic malignancy, highlights the importance of greater collaboration between oncology and dermatology services to mitigate the impact of these events on both quality of life and outcome, wrote Gregory S. Phillips of Memorial Sloan Kettering Cancer Center, New York, and his associates. The study was published in the Journal of the American Academy of Dermatology.

The data that produced these conclusions were drawn from a retrospective chart review of 11,533 cancer patients treated at the center during 2015. Of these, 412 (3.6%) were referred for a dermatology consultation.

Those who received a dermatology consultation were comparable for median age (60 years) and gender (roughly 50:50 male:female), compared with those who did not. However, the odds ratio (OR) for a dermatology consultation was 6.56 among those with a hematologic malignancy compared with those who had a solid tumor. In those with leukemia, the proportion receiving a dermatologic consult was nearly ninefold greater.

Whether or not undertaken in a patient with a hematologic malignancy, dermatologic consults correlated with significantly greater morbidity, as well as mortality. This included a longer median length of stay (11 vs. 5 days; P less than .0001) and a higher in-hospital rate of death (9% vs. 2%; P less than .0001), compared with patients not needing a dermatology consultation.

Of dermatologic consultations in the total study population, the most common were for inflammatory conditions (27%), infections (24%), and drug reactions (17%). Neoplasm was the dermatologic diagnosis in 10% of the total population, but in 13% of those with hematologic malignancies.

Inpatient dermatology consultations were most frequently ordered by the hematology-oncology service, accounting for 44% of the total, followed by the solid tumor oncology service (27%) and the surgery service (15%). Multiple consultations were more likely in patients with leukemia or lymphoma than other forms of cancer.

Pages

Recommended Reading

Subsequent squamous cell carcinoma risk higher in HIV patients with low CD4 count
MDedge Hematology and Oncology
MAVORIC: Mogamulizumab tops vorinostat in pretreated CTCL
MDedge Hematology and Oncology
Pemphigus associated with higher risk of hematologic malignancies
MDedge Hematology and Oncology
Autologous stem-cell transplantation for scleroderma beats cyclophosphamide in long term
MDedge Hematology and Oncology
Supportive oncodermatology: Cancer advances spawn new subspecialty
MDedge Hematology and Oncology
Cutaneous multiple myeloma is a deadly indicator
MDedge Hematology and Oncology
Lenalidomide yields responses in a rare cutaneous lymphoma
MDedge Hematology and Oncology
Grind it out
MDedge Hematology and Oncology
MDedge Daily News: Which nonopioids are ripe for abuse?
MDedge Hematology and Oncology
Probe linked to smartphone found effective in diagnosing oral cancer
MDedge Hematology and Oncology